Medtronic is the world’s leading medical technology company, providing lifelong solutions for people with chronic disease. With deep roots in the treatment of heart disease, Medtronic now provides a wide range of products and therapies that help physicians solve the most challenging, life-limiting medical problems and restore health, extend life, and alleviate pain. Medtronic Ibérica S.A. operates in Spain distributing products, performing clinical research and running educational programs to medical professionals involved in the areas and therapies of our expertise. The workforce in Spain is now more than 170 employees.
Cardiac Rhythm Disease Management manages the full spectrum of cardiac rhythm disorders to improve long-term patient care. The solutions developed at Medtronic allow physicians to monitor and treat their patients' changing cardiac conditions throughout a lifetime. These developments include pacemakers to treat patients with bradycardia; implantable defibrillators to help patients with tachyarrhythmia; and diagnostic and monitoring innovations that diagnose heart-related syncope. Other business areas of Medtronic include Neuromodulation, Spinal and Biologics, Diabetes, CardioVascular and Ear Nose & Throat (ENT) products and techniques.

Tasks attributed and relevant prior experience
Medtronic will take role in CIED related tasks such as CIED based Personalized Adaptive Care Planner Engine, Exposing CIED Data through Standard Interfaces. Medtronic will provide standards-compliant (HL7 preferred) data sets of ICD data from patients who will take part in the study. Additionally, Medtronic will provide experts of ICDs to guide researchers in integrating Medtronic remote facilities into the intended iCARDEA Platform.
The Medtronic CareLink Network is a remote patient management system that supports and integrates onto one platform the combination of devices ranging from pacemakers, ICDs, CRT-Ds and ICMs. This comprehensive tool makes remote management available to new patients and to those already treated with device therapy or diagnostics. Prospective trials have shown that the Medtronic CareLink Network can offer a safe and feasible solution, allowing time and cost savings for follow-up visits in patients with heart devices¹. Earlier management of clinical events may also improve overall patient care according to studies². To date, more than 450 hospitals in Europe already manage more than 12,000 patients at risk of heart failure and atrial fibrillation through the Medtronic CareLink Network.
Furthermore, Medtronic is developing a system called Paceart that aims to organize relevant patient, device and programmer information to help the physician meet the clinic management challenge. The objectives of Paceart are in parallel with the objectives of iCARDEA; hence both parties will benefit from each other. At the end, perfect exploitation for the European industry will be achieved.
Medtronic treasures expertise in implantable arrhythmia management systems & clinical research along with a fluent relationship with key opinion leaders and experts in the cardiology field.

Website: http://www.medtronic.es